Bullous pemphigoid (BP) is an autoimmune disorder known to be mediated by immunoglobulin G (IgG) autoantibodies. The role of immunoglobulin E (IgE) antibodies is being investigated as their presence has been described in severe cases. Herein, we report a patient of BP who was refractory to most conventional agents and developed hypotension after rituximab but achieved lasting remission after a single dose of the anti-IgE monoclonal antibody omalizumab.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413437 | PMC |
| http://dx.doi.org/10.4103/idoj.IDOJ_438_19 | DOI Listing |
Publication Analysis
Top Keywords
bullous pemphigoid
8
single dose
8
complete remission
4
remission patient
4
patient treatment
4
treatment refractory
4
refractory bullous
4
pemphigoid single
4
dose omalizumab
4
omalizumab bullous
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!